Abstract
Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8-7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R) scintigraphy in our patients. In vitro data also demonstrated absence of SSTR2 expression, suggesting pancreatic cancer not to be a potential target for treatment with SST analogues.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / pathology
-
Adult
-
Aged
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Female
-
Humans
-
Injections, Intramuscular
-
Male
-
Middle Aged
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / pathology
-
Peptides, Cyclic / pharmacology
-
Peptides, Cyclic / therapeutic use*
-
Receptors, Somatostatin / biosynthesis
-
Receptors, Somatostatin / drug effects
-
Somatostatin / analogs & derivatives*
-
Somatostatin / pharmacology
-
Somatostatin / therapeutic use
-
Survival Analysis
Substances
-
Antineoplastic Agents
-
Peptides, Cyclic
-
Receptors, Somatostatin
-
lanreotide
-
Somatostatin